Literature DB >> 23532504

[Pathophysiology of acne. What is confirmed?].

C C Zouboulis1.   

Abstract

Acne is the most common skin disease worldwide. Choosing the appropriate therapeutic regimens for the clinically diversified disease phenotypes require good knowledge of its pathophysiology. New concepts in this field have been developed in the last 15 years. Acne vulgaris is an inflammatory disorder in which androgens, PPAR ligands, regulating neuropeptides and environmental factors are probably involved as triggers. These factors interrupt the natural cycling process in the sebaceous gland follicle and support the transition of microcomedones to comedones and clinically inflammatory lesions. Proinflammatory lipids, chemokines and cytokines overtake the role of mediators for the further development of acne lesions. Bacterial antigens can potentate the inflammatory phenomena.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532504     DOI: 10.1007/s00105-012-2457-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  31 in total

Review 1.  Comedogenesis: some new aetiological, clinical and therapeutic strategies.

Authors:  W J Cunliffe; D B Holland; S M Clark; G I Stables
Journal:  Br J Dermatol       Date:  2000-06       Impact factor: 9.302

2.  Digital image analysis of the effect of topically applied linoleic acid on acne microcomedones.

Authors:  C Letawe; M Boone; G E Piérard
Journal:  Clin Exp Dermatol       Date:  1998-03       Impact factor: 3.470

3.  Zileuton, a new efficient and safe systemic anti-acne drug.

Authors:  Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2009-05

4.  Peroxisome proliferator-activated receptors increase human sebum production.

Authors:  Nishit R Trivedi; Zhaoyuan Cong; Amanda M Nelson; Adam J Albert; Lorraine L Rosamilia; Surendra Sivarajah; Kathryn L Gilliland; Wenlei Liu; David T Mauger; Robert A Gabbay; Diane M Thiboutot
Journal:  J Invest Dermatol       Date:  2006-05-04       Impact factor: 8.551

5.  Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands.

Authors:  Theodosios Alestas; Ruta Ganceviciene; Sabine Fimmel; Karin Müller-Decker; Christos C Zouboulis
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

6.  An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study.

Authors:  A C Jahns; B Lundskog; R Ganceviciene; R H Palmer; I Golovleva; C C Zouboulis; A McDowell; S Patrick; O A Alexeyev
Journal:  Br J Dermatol       Date:  2012-06-01       Impact factor: 9.302

7.  The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.

Authors:  J Imperato-McGinley; T Gautier; L Q Cai; B Yee; J Epstein; P Pochi
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

8.  Modeling acne in vitro.

Authors:  R Guy; M R Green; T Kealey
Journal:  J Invest Dermatol       Date:  1996-01       Impact factor: 8.551

9.  Dietary intervention in acne: Attenuation of increased mTORC1 signaling promoted by Western diet.

Authors:  Bodo Melnik
Journal:  Dermatoendocrinol       Date:  2012-01-01

10.  Expression pattern of cyclooxygenase-2 in normal rat epidermis and pilosebaceous unit during hair cycle.

Authors:  Yuanxu Xu; Li Yang; Tian Yang; Mingming Xiang; Enyi Huang; Xiaohua Lian
Journal:  Acta Histochem Cytochem       Date:  2008-10-28       Impact factor: 1.938

View more
  3 in total

Review 1.  [Acne and rosacea in pregnancy].

Authors:  S K Bechstein; F Ochsendorf
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

2.  [Acne vulgaris].

Authors:  C C Zouboulis
Journal:  Hautarzt       Date:  2014-08       Impact factor: 0.751

Review 3.  New developments in acne treatment: role of combination adapalene-benzoylperoxide.

Authors:  Su Youn Kim; Falk R Ochsendorf
Journal:  Ther Clin Risk Manag       Date:  2016-10-03       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.